Company intelligence / Profile preview

Tollo Health

Tampa, Florida, United Statestollohealth.com ↗

Ownership: Private
Development stage: Commercial

Overview

Tollo Health develops and markets proprietary medical food products designed to address muscle loss and gut discomfort associated with GLP‑1 drug use as well as symptoms of Long COVID. Their lead product, Galectovid®, targets galectin proteins implicated in viral persistence. The company’s products are distributed through pharmacy networks in partnership with Wellgistics. There are no published clinical trial results but the products are positioned as natural solutions backed by scientific research.

Therapeutic areas: Metabolic DisordersEndocrinologyImmunologyOtherGastroenterologyCardiovascularInfectious Diseases
Modalities: Medical foodSmall moleculeNutritional supplement
Industry: Food & Nutrition

Partnerships

Wellgistics LLC/Wellgistics Health Inc.

Beyond the preview

Go deeper on Tollo Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tollo Health.

Explore the full profile